Fate Therapeutics

Novocure's electrical field-emitting device in Phase 3 trial showed extended survival in pancreatic cancer patients when used with chemo; Merus licensed U.S. rights of its cancer drug zenocutuzumab to Partner Therapeutics; FDA to decide on Cytokinetics' heart drug aficamten approval by Sept. 26, 2025; FDA investigates blood cancer cases post-Bluebird bio's Skysona treatment; Fate Therapeutics' CEO Scott Wolchko to retire, with Bob Valamehr taking over in 2025.

Fate Therapeutics announces Scott Wolchko's retirement as President and CEO, effective December 31, 2024, and Bob Valamehr's appointment as his successor starting January 1, 2025. Wolchko led the company in pioneering iPSC-derived cellular immunotherapies for cancer and autoimmune disorders, while Valamehr, currently President of R&D, has been instrumental in developing the iPSC platform.

The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.

Chat with this insight to save time by focusing on key points.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

FT825 / ONO-8250, a CAR T-cell product targeting HER2, showed favorable safety and efficacy in Phase 1 solid tumor study, with no dose-limiting toxicities observed. Preclinical data highlighted its cancer-selective recognition profile, targeting HER2 variants uniquely expressed on tumor cells.

FT825 / ONO-8250, a CAR T-cell product targeting HER2, showed favorable safety and efficacy in Phase 1 solid tumor study, with no dose-limiting toxicities observed. Preclinical data highlighted the cancer-selective recognition profile of its novel HER2 antigen binding domain, derived from H2CasMab-2, which preferentially targets tumor cells.

Fate Therapeutics presented preclinical data for FT836, a CAR T-cell product targeting MICA/B proteins, at the 2024 SITC Annual Meeting, demonstrating robust anti-tumor activity across solid tumors and potential for combination therapies.